Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 2, 2027

Study Completion Date

December 2, 2029

Conditions

Uterine Leiomyosarcoma

Interventions

DRUG

Trabectedin

Given by IV Infusion

DRUG

Doxorubicin Hydrochloride

Given by IV Infusion

Trial Locations (1)

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER